Janney Montgomery Scott LLC Has $1.34 Million Holdings in UiPath Inc. (NYSE:PATH)

Janney Montgomery Scott LLC grew its holdings in shares of UiPath Inc. (NYSE:PATH) by 17.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 104,608 shares of the healthcare company’s stock after acquiring an additional 15,698 shares during the quarter. Janney Montgomery Scott LLC’s holdings in UiPath were worth $1,339,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in PATH. Allspring Global Investments Holdings LLC increased its position in UiPath by 819.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 19,209 shares of the healthcare company’s stock worth $435,000 after purchasing an additional 17,120 shares in the last quarter. Empowered Funds LLC boosted its holdings in shares of UiPath by 10.5% during the 1st quarter. Empowered Funds LLC now owns 10,856 shares of the healthcare company’s stock valued at $246,000 after acquiring an additional 1,033 shares in the last quarter. Sei Investments Co. boosted its holdings in shares of UiPath by 51.7% during the 1st quarter. Sei Investments Co. now owns 69,016 shares of the healthcare company’s stock valued at $1,565,000 after acquiring an additional 23,529 shares in the last quarter. Russell Investments Group Ltd. grew its position in UiPath by 96.6% during the 1st quarter. Russell Investments Group Ltd. now owns 75,851 shares of the healthcare company’s stock worth $1,720,000 after acquiring an additional 37,267 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in UiPath by 79.8% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 39,263 shares of the healthcare company’s stock worth $890,000 after purchasing an additional 17,423 shares in the last quarter. Institutional investors own 62.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on PATH. DA Davidson upped their price objective on UiPath from $13.00 to $15.00 and gave the company a “neutral” rating in a research note on Friday, September 6th. Needham & Company LLC restated a “hold” rating on shares of UiPath in a research report on Wednesday, October 23rd. Barclays lifted their price target on shares of UiPath from $14.00 to $15.00 and gave the stock an “equal weight” rating in a report on Friday, September 6th. TD Cowen decreased their price objective on UiPath from $17.00 to $16.00 and set a “hold” rating for the company in a report on Friday, September 6th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $15.00 target price on shares of UiPath in a research report on Friday, September 6th. Sixteen investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $17.47.

Insider Buying and Selling

In related news, CFO Ashim Gupta sold 47,671 shares of UiPath stock in a transaction on Friday, September 13th. The shares were sold at an average price of $12.07, for a total value of $575,388.97. Following the completion of the sale, the chief financial officer now owns 849,917 shares of the company’s stock, valued at approximately $10,258,498.19. This trade represents a 5.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 22.37% of the stock is owned by company insiders.

UiPath Stock Performance

Shares of PATH opened at $12.63 on Friday. The firm has a market cap of $6.95 billion, a PE ratio of -63.15 and a beta of 0.87. UiPath Inc. has a 52-week low of $10.37 and a 52-week high of $27.87. The business’s 50 day moving average price is $12.60 and its two-hundred day moving average price is $13.47.

UiPath (NYSE:PATH) last issued its earnings results on Thursday, September 5th. The healthcare company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.01. UiPath had a negative net margin of 8.13% and a negative return on equity of 3.98%. The business had revenue of $316.00 million for the quarter, compared to analyst estimates of $303.69 million. During the same period in the prior year, the firm earned ($0.09) earnings per share. UiPath’s revenue was up 10.0% on a year-over-year basis. Research analysts predict that UiPath Inc. will post -0.23 EPS for the current fiscal year.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.